Melin­ta Ther­a­peu­tics nabs FDA nod for more con­ve­nient re­work of an­tibi­ot­ic Or­bac­tiv, a for­mer Eli Lil­ly can­di­date

As pres­sure ris­es to ad­dress the su­per­bug cri­sis, Melin­ta Ther­a­peu­tics says it now has a more con­ve­nient op­tion to treat those with an­tibi­ot­ic-re­sis­tant skin in­fec­tions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER